scPharmaceuticals Inc a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that the U.S. Food and Drug Administration (FDA) has approved FUROSCIX® (furosemide injection), a proprietary formulation of furosemide delivered via an On-Body Infusor for the treatment of congestion due to fluid overload in adults with New York Heart Association Class II/III chronic heart failure.
- Read more about FDA nods furosemide inj for at home treatment of congestion in CHF
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/fda-nods-furosemide-inj-for-at-home-treatment-of-congestion-in-chf
No comments:
Post a Comment